Relapsed/Refractory Hodgkin Lymphoma

Sep 16, 2017 by in HEMATOLOGY Comments Off on Relapsed/Refractory Hodgkin Lymphoma

For relapsed-refractory Hodgkin Lymphoma, standard therapy consists of salvage chemotherapy followed by autologous stem cell transplantation. Adverse risk factors at relapse include response duration less than 12 months, advanced stage,…

read more

Customized Targeted Therapy in Hodgkin Lymphoma

Sep 16, 2017 by in HEMATOLOGY Comments Off on Customized Targeted Therapy in Hodgkin Lymphoma

Although most patients with Hodgkin lymphoma (HL) are cured with primary therapy, patients with primary refractory disease or relapse after initial treatment have poor outcomes and represent an unmet medical…

read more

FDG-PET Response–adapted Therapy

Sep 16, 2017 by in HEMATOLOGY Comments Off on FDG-PET Response–adapted Therapy

Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is the most accurate tool for staging, treatment monitoring, and response evaluation in Hodgkin lymphoma (HL). Early determination of treatment sensitivity by…

read more

Combination Chemoradiotherapy in Early Hodgkin Lymphoma

Sep 16, 2017 by in HEMATOLOGY Comments Off on Combination Chemoradiotherapy in Early Hodgkin Lymphoma

Combination chemoradiotherapy achieves excellent results for the treatment of localized Hodgkin lymphoma. However, late toxic effects occur, mostly related to the radiotherapy administered after the standard adriamycin, bleomycin, vinblastine, and…

read more

Advancing Antibody Drug Conjugation

Sep 16, 2017 by in HEMATOLOGY Comments Off on Advancing Antibody Drug Conjugation

The concept of using monoclonal antibodies for delivering drugs to cancer cells has been explored for decades, with early work surrounding nonspecific targets and drugs with low potencies. These studies…

read more

First Hodgkin Cell Line L428 and the CD30 Antigen

Sep 16, 2017 by in HEMATOLOGY Comments Off on First Hodgkin Cell Line L428 and the CD30 Antigen

Hodgkin’s disease (HD) is a fatal disorder with the unique histologic features of few dysplastic Hodgkin- and Reed-Sternberg (HRS) cells surrounded by an abundance of nonatypical bystander cells in primary…

read more
Get Clinical Tree app for offline access